Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 320

Sort by

Sort Order Select

Journal Articles

DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in B-cell Acute Lymphoblastic Leukemia

Blood blood.2024026085.

https://doi.org/10.1182/blood.2024026085

Published: 2024

Includes: Supplemental data

Journal Articles

A Niche Driven Mechanism Determines Response to ATRA and a Mutation-Independent Therapeutic Approach for MDS and AML

Ioanna Mosialou, Abdullah Mahmood Ali, Alvaro Cuesta-Dominguez, Rossella Labella, Voula Vgenopoulou, Brygida Bisikirska, Marta Galan-Diez, Anqi Wang, Jan Philipp Bewersdorf, Cui Liang, Mael Heiblig, Joseph G Jurcic, Ellin Berman, Raul Rabadan, Steven M. Kornblau, Guillermo Garcia-Manero, Azra Raza, Stavroula Kousteni

Blood (2024) 144 (Supplement 1): 5788.

https://doi.org/10.1182/blood-2024-212307

Published: 2024

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Journal Articles

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Jennifer Marvin-Peek, Hagop M. Kantarjian, Wei-Ying Jen, Gautam Borthakur, Naval Daver, Abhishek Maiti, Nicholas J. Short, Steven M. Kornblau, Naveen Pemmaraju, Eitan Kugler, Alexandre Bazinet, Yesid Alvarado-Valero, Hussein A. Abbas, Guillermo Garcia-Manero, Uday Popat, Elizabeth J. Shpall, Farhad Ravandi, Courtney D. DiNardo, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 3572.

https://doi.org/10.1182/blood-2024-202414

Published: 2024

Journal Articles

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Blood (2024) 144 (Supplement 1): 6126.

https://doi.org/10.1182/blood-2024-207413

Published: 2024

Journal Articles

EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

Carolin S. Escherich, Zhenhua Li, Kelly R. Barnett, Yizhen Li, Megan Walker, Wenjian Yang, Xin Huang, Jiyang Yu, Wendy Stock, Elisabeth Paietta, Marina Konopleva, Steven M. Kornblau, Mark R. Litzow, Hiroto Inaba, Ching-Hon Pui, Mignon L. Loh, Daniel Savic, Jun J. Yang

Blood (2024) 144 (Supplement 1): 830.

https://doi.org/10.1182/blood-2024-198800

Published: 2024

Journal Articles

Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML

Blood (2024) 144 (Supplement 1): 53.

https://doi.org/10.1182/blood-2024-211997

Published: 2024

Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2024-204040

Published: 2024

Journal Articles

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood (2024) 144 (Supplement 1): 1855.

https://doi.org/10.1182/blood-2024-211110

Published: 2024

Journal Articles

The Mitochondrial Unfolded Protein Response (UPR mt ) Is Upregulated in Acute Myeloid Leukemia (AML) and Inhibiting the UPR mt Protease, LONP1, Leads to Mitochondrial Protein Aggregation and Cell Death Selectively in AML

Matthew Tcheng, Veronique Voisin, Marcela Gronda, Rose Hurren, Dakai Ling, Yongran Yan, Lan Xin Zhang, Yue Feng, Zaynab Mamai, Yulia Jitkova, Chaitra Sarathy, Andrea Arruda, Steven M. Kornblau, Mark D. Minden, Aaron D Schimmer

Blood (2024) 144 (Supplement 1): 2778.

https://doi.org/10.1182/blood-2024-205308

Published: 2024

Journal Articles

Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker

Hussein A. Abbas, Bofei Wang, Jennifer Marvin-Peek, Bin Yuan, Araceli Isabella Garza, Jessica Lynn Root, Andrea Arruda, Yiwei Liu, Courtney D. DiNardo, Tapan M. Kadia, Naval Daver, Philip L Lorenzi, Koji Sasaki, Steven M. Kornblau, Mark D. Minden, Farhad Ravandi, Hagop M. Kantarjian, Patrick K. Reville

Blood (2024) 144 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2024-201725

Published: 2024

Journal Articles

Proteomics-Based Approach Recognize Unique Expression Profiles in Adult Acute Monocytic/Monoblastic Leukemia: Implications for Prognostication and Drug Repurposing

Eduardo Sabino De Camargo Magalhaes, Brandon D. Brown, Yihua Qiu, Steven M. Kornblau

Blood (2024) 144 (Supplement 1): 2942.

https://doi.org/10.1182/blood-2024-208114

Published: 2024

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2024) 144 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2024-204296

Published: 2024

Journal Articles

Identification of Prognostic Signatures and Potential New Therapies in NPM1 Mutant Adult Acute Myeloid Leukemia Patients Using Proteomics

Eduardo Sabino De Camargo Magalhaes, Brandon D. Brown, Yihua Qiu, Steven M. Kornblau

Blood (2024) 144 (Supplement 1): 1534.

https://doi.org/10.1182/blood-2024-204068

Published: 2024

Journal Articles

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy

Blood (2024) 144 (Supplement 1): 2896.

https://doi.org/10.1182/blood-2024-198541

Published: 2024

Journal Articles

A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 833.

https://doi.org/10.1182/blood-2023-172658

Published: 2023

Journal Articles

Optimizing FLT3 Inhibitor Use in Adult Acute Myeloid Leukemia with FLT3 Mutations Using Proteomics

Eduardo Sabino Magalhaes, Stefan Hubner, Brandon D. Brown, Yihua Qiu, Steven M. Kornblau

Blood (2023) 142 (Supplement 1): 165.

https://doi.org/10.1182/blood-2023-186508

Published: 2023

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2023) 142 (Supplement 1): 158.

https://doi.org/10.1182/blood-2023-186699

Published: 2023

Journal Articles

The Impact of Age and Genomics on Drug Sensitivity in 1,076 Children and Adults with B-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 596.

https://doi.org/10.1182/blood-2023-181788

Published: 2023

Journal Articles

Proteomic Profiling Identifies Unique IDH Mutant Signatures and Novel Therapeutic Opportunities in Adult Acute Myeloid Leukemia Patients

Eduardo Sabino de Camargo Magalhaes, Stefan Hubner, Brandon D. Brown, Yihua Qiu, Steven M. Kornblau

Blood (2023) 142 (Supplement 1): 1581.

https://doi.org/10.1182/blood-2023-186723

Published: 2023

NARROW

DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in B-cell Acute Lymphoblastic Leukemia

A Niche Driven Mechanism Determines Response to ATRA and a Mutation-Independent Therapeutic Approach for MDS and AML

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

The Mitochondrial Unfolded Protein Response (UPR mt ) Is Upregulated in Acute Myeloid Leukemia (AML) and Inhibiting the UPR mt Protease, LONP1, Leads to Mitochondrial Protein Aggregation and Cell Death Selectively in AML

Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker

Proteomics-Based Approach Recognize Unique Expression Profiles in Adult Acute Monocytic/Monoblastic Leukemia: Implications for Prognostication and Drug Repurposing

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Identification of Prognostic Signatures and Potential New Therapies in NPM1 Mutant Adult Acute Myeloid Leukemia Patients Using Proteomics

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy

A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia

Optimizing FLT3 Inhibitor Use in Adult Acute Myeloid Leukemia with FLT3 Mutations Using Proteomics

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

The Impact of Age and Genomics on Drug Sensitivity in 1,076 Children and Adults with B-Cell Acute Lymphoblastic Leukemia

Proteomic Profiling Identifies Unique IDH Mutant Signatures and Novel Therapeutic Opportunities in Adult Acute Myeloid Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only